Tue, Jan 13, 2026 | Updated 08:10 IST
Nov 08, 2021
Bengaluru (Karnataka) [India]/ Saratoga (California) [US]/ Adelaide [Australia], November 8 (ANI/PRNewswire): Bugworks research today announced that the first human dose was administered in a Phase 1 clinical trial evaluating BWC0977: a next generation broad-spectrum, novel bacterial topoisomerase inhibitor (NBTI), supported by Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).
New Delhi [India], November 8 (ANI/ATK): The Tanishq 'Utsah' film has really been a clutter breaker!
Nov 07, 2021
More News
Nov 06, 2021
Kota (Rajasthan) [India], November 6 (ANI/PNN): After a long delay, NEET (UG) 2021 was declared by NTA on...
New Delhi [India], November 6 (ANI/NewsVoir): India's leading tax lawyer and well known international tax and policy expert,...
Bhubaneswar (Odisha) [India], November 6 (ANI/PNN): Tankadhar Tripathy has been appointed as Director on the Board of Directors...
Nov 05, 2021
Nov 04, 2021